Gland Pharma Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ejxn9oi99zsaqziyatwn90e6.pdf

Key Takeaways


Cenexi Integration: The Quarter’s Central Problem

Srinivas Sadu: "These operational issues are causing delays in supplies and augmenting a backlog of orders."

Base Business Margins


U.S. Market: Volume Momentum, Stable Pricing

Srinivas Sadu: "We're confident that we'll end the fiscal year '24 positively and continue to be excited about the opportunities ahead of us."

Ex-U.S. Markets: Rest of World Picks Up, India Steps Back


Product Pipeline & Future Growth Levers


Guidance & Commitments

CommitmentSpecificsTimeline
Cenexi acquisition thesis realizationPlan to realize the original acquisition thesisNext 12 to 15 months
Cenexi EBITDA breakevenBreak even at EBITDA levelNext 12 to 15 months
Cenexi EBITDA margin targetAchieve 10% EBITDA marginMidterm; FY25 described as reasonable
Cenexi incremental revenue from tech transfersEUR 3 crore to EUR 4 crore incremental annual revenueFY26
Cenexi go-forward D&A from PPAApproximately INR 9 crore to INR 14 crore per quarterOngoing from Q3 FY24
Consolidated depreciationAround INR 90 crores per quarterGoing forward
Ex-Cenexi growth ambitionMid-teens growth target internallyNext 2 to 3 years
U.S. revenue trajectorySteady growth to continueAt least in the near term

Key Metrics

MetricQ3 FY24
Revenue₹1,545.2 cr, +65% YoY and +13% QoQ
Base business revenue (ex-Cenexi)+17% YoY and +9% QoQ
Gross margin61%, improved from 54% in Q3 FY23
EBITDA₹355.7 cr, +23% YoY
EBITDA margin23%, compared to 31% in Q3 FY23
Base business EBITDA margin (ex-Cenexi)34%, up from 31% in Q3 FY23
Net profit₹191.9 cr, -17% YoY and -1% QoQ
PAT margin12%
R&D expenses₹53 cr, 5% of operating revenue (ex-Cenexi basis)
U.S. revenue~₹820 cr, +12% QoQ and +41% YoY
U.S. growth drivers8% from volumes, 3% from new launches, remainder from milestone and profit shares
Cenexi revenue₹443.9 cr, gross contribution of 75%
Cenexi EBITDANegative ₹17 cr, impacted by one-time expenses and lower productivity
Cash and equivalents (net)₹2,070.4 cr, gross cash of ₹2,479.5 cr less loans of ₹405.8 cr
Cash conversion cycle182 days for nine months ending Dec 2023, improved from 240 days in same period last year
ANDAs filed during quarter10 filed, 3 approved
Cumulative ANDAs346 filed, 279 approved, 67 pending as of Dec 31, 2023
Capex (quarter)₹81 cr
Capex outlook (next financial year)~₹300 cr for Gland Pharma capacity expansion